Back to News
Market Impact: 0.18
Telix Completes Patient Enrollment In BiPASS Trial, Aligns With FDA On NDA Filing; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Telix Pharmaceuticals (TLX) reported completion of patient enrollment in its Phase 3 BiPASS study evaluating its PSMA-PET imaging agents Illuccix and Gozellix for prostate cancer. The update is a positive clinical milestone, though no efficacy/readout results were disclosed yet. Overall, the news is likely to have limited near-term market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
TLX0.25
More News
- Palantir patient data tech rejected by many NHS trusts in England
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- Diageo's Toxic Spill Hits Pristine River in Scottish Whisky Country
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated